M Pharmaceutical (CSE:MQ) has welcomed gastroenterologist Dr. Christopher Andrews, M.D.to its Board.
Dr. Andrews is a faculty member of the Department of Medicine at the University of Calgary and graduate of the Mayo Clinic in Rochester, MN. He specializes in stomach disorders and physiology.
M Pharma considers Dr. Andrews, who also specializes in the development of novel diagnostic and therapeutic methods related to gut function, to be a valuable leadership asset to the company as it advances its development of biomedical technologies targeting obesity and diabetes and:
"His addition to our Board of Directors will help ensure that we make the most of our vision and strategic plan reflected in technologies such as the e-Mosquito wearable blood glucose monitor, the implantable gastro-intestinal neuro stimulators and the ingestible pseudobezoars," said M Pharma’s President and CEO, Dr. Martin Mintchev.
Dr. Andrews has won such awards as ‘Young Investigator Award’ from the American Motility Society for his research on the effects of glucagon-like peptide-1 on gastric accommodation. He has also published over 50 peer-reviewed articles and has numerous teaching citations from the University of Calgary Medical School.
Dr. Andrews will take up the seat on the Board left vacant by David Lane, who has played important role in building M Pharma as its inaugural president.